Celgene's (CELG +1.9%) apremilast treatment for psoriatic arthritis meets primary efficacy goals...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene's (CELG +1.9%) apremilast treatment for psoriatic arthritis meets primary efficacy goals in a Phase 3 study, and the biotech will now seek FDA and EU regulatory approval for the drug in 2013. Apremilast also achieved its primary goal in a separate study of patients with Behcet's disease, a rare inflammatory condition. (PR)